Quidel Co. (NASDAQ:QDEL) Director Jack W. Schuler sold 4,000 shares of the stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $47.02, for a total transaction of $188,080.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Quidel Co. (NASDAQ:QDEL) opened at $46.17 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.68 and a current ratio of 6.28. The firm has a market cap of $1,560.00, a PE ratio of -288.56, a price-to-earnings-growth ratio of 1.51 and a beta of 1.15. Quidel Co. has a 12 month low of $18.25 and a 12 month high of $47.60.
Quidel (NASDAQ:QDEL) last announced its earnings results on Wednesday, November 1st. The company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by ($0.21). Quidel had a negative return on equity of 2.36% and a negative net margin of 2.33%. The company had revenue of $50.89 million for the quarter, compared to analysts’ expectations of $50.47 million. During the same period last year, the business earned $0.10 EPS. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. equities analysts forecast that Quidel Co. will post -0.23 EPS for the current year.
A number of equities research analysts recently issued reports on QDEL shares. Piper Jaffray Companies raised shares of Quidel from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $35.00 to $50.00 in a report on Tuesday, September 19th. Canaccord Genuity reissued a “buy” rating and issued a $48.00 price objective (up previously from $42.00) on shares of Quidel in a report on Tuesday, September 19th. CL King raised shares of Quidel from a “neutral” rating to a “buy” rating and set a $52.00 price objective for the company in a report on Thursday, January 4th. Zacks Investment Research lowered shares of Quidel from a “hold” rating to a “strong sell” rating in a report on Thursday, December 28th. Finally, BidaskClub raised shares of Quidel from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $50.00.
TRADEMARK VIOLATION WARNING: “Insider Selling: Quidel Co. (QDEL) Director Sells 4,000 Shares of Stock” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2018/01/12/insider-selling-quidel-co-qdel-director-sells-4000-shares-of-stock.html.
Quidel Company Profile
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
What are top analysts saying about Quidel? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Quidel and related companies.